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Abstract
Background: In a star-shaped network, pairwise comparisons link treatments with a reference treatment (often
placebo or standard care), but not with each other. Thus, comparisons between non-reference treatments rely on
indirect evidence, and are based on the unidentifiable consistency assumption, limiting the reliability of the results.
We suggest a method of performing a sensitivity analysis through data imputation to assess the robustness of
results with an unknown degree of inconsistency.
Methods: The method involves imputation of data for randomized controlled trials comparing non-reference
treatments, to produce a complete network. The imputed data simulate a situation that would allow mixed
treatment comparison, with a statistically acceptable extent of inconsistency. By comparing the agreement between
the results obtained from the original star-shaped network meta-analysis and the results after incorporating the
imputed data, the robustness of the results of the original star-shaped network meta-analysis can be quantified and
assessed. To illustrate this method, we applied it to two real datasets and some simulated datasets.
Results: Applying the method to the star-shaped network formed by discarding all comparisons between non-
reference treatments from a real complete network, 33% of the results from the analysis incorporating imputed
data under acceptable inconsistency indicated that the treatment ranking would be different from the ranking
obtained from the star-shaped network. Through a simulation study, we demonstrated the sensitivity of the results
after data imputation for a star-shaped network with different levels of within- and between-study variability. An
extended usability of the method was also demonstrated by another example where some head-to-head
comparisons were incorporated.
Conclusions: Our method will serve as a practical technique to assess the reliability of results from a star-shaped
network meta-analysis under the unverifiable consistency assumption.
Keywords: Star-shaped network, Indirect comparisons, Network meta-analysis, Inconsistency, Sensitivity analysis,
Data imputation
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Background
Network meta-analyses based on systematic reviews are
often used to produce evidence for medical decision-
making, such as deciding which of various treatment
options is the best for a pre-defined population of pa-
tients. Specifically, network meta-analysis is a statistical
method for integrating the data available from a network
of multiple randomized controlled trials (RCTs) that
involve multiple interventions, to estimate their relative
effects by comparing them directly, indirectly, or both
[1, 2]. The objective of a network meta-analysis is to
compare the relative efficacy and/or safety of multiple
medical interventions and to rank each treatment for a
corresponding outcome [3].
Since a network meta-analysis combining all informa-
tion from RCTs on multiple interventions provides an
internally coherent set of estimates of the relative treat-
ment effects between competing interventions [4–6], the
included trials should be comparable; that is, there
should be no imbalance in the distribution of potential
effect modifiers across the trials [7–9]. In principle this
should ensure consistency of evidence, however the
assumption of consistency across direct and indirect evi-
dence should also be statistically checked [10–12]. When
the assumption of consistency is satisfied, a network
meta-analysis may have acceptable validity, whereas this
will be questionable when inconsistency, characterized
by a discrepancy between direct and indirect evidence, is
found [13]. However checking the consistency of the dir-
ect and indirect evidence in a network is only feasible
when there are one or more closed loops within an evi-
dence network. A closed loop refers to a part of a net-
work where each comparison has both direct and
indirect evidence [14]. Methods of testing for inconsist-
ency in a network have been previously presented, and
are distinguished by how to treat inconsistency [10–12,
15–17]. If the consistency assumption is violated in a
network, a further qualitative evaluation is necessary to
identify its sources [7–9].
However, researchers might encounter an evidence
network where all treatments have been compared only
with a common treatment, but not with each other. For
example, new drugs are often compared with placebo or
standard care, rather than to active treatments, in trials
conducted for the purpose of obtaining approval for
drug licensing [18]. Once a drug receives regulatory ap-
proval, there may no longer be any commercial incentive
to compare the drug against other alternatives, and
therefore there are occasions where no head-to-head tri-
als between active treatments exist [19]. Such networks
do not have any closed loops, and are referred to as
‘star-shaped networks’ [20]. A study reported that 47
(31%) of 152 network analyses published in PubMed be-
tween inception and March 2011 included star-shaped
networks [21]. Although a decade has passed since then,
many network meta-analyses still consist of interven-
tions that do not have both indirect and direct compari-
sons or are conducted in contexts where one or few
closed loops are available. For example, with advances of
biologics for the treatment of rheumatoid arthritis over
the past two decades, its evidence network, which in-
cluded only indirect evidence in the first decade, has
now incorporated some (albeit few) head-to-head
comparisons [22]. In a star-shaped network, statistically
detecting or checking inconsistency is impossible, thus
researchers need to rely solely on a qualitative evaluation
that studies are comparable, before integrating the data
into a network meta-analysis under the consistency
assumption [23–25]. However, there may be a certain
degree of inconsistency between the evidence from the
included indirect comparisons and the unknown direct
comparisons; it may be impossible to detect statistically,
but should nonetheless be considered. Therefore, it is
necessary to explore the degree to which results from
a star-shaped network are robust to potential
inconsistencies.
In this article, we suggest a sensitivity analysis for
evaluating the robustness of the results of a star-shaped
network meta-analysis, and illustrate some examples of
applying the method to two real datasets and four simu-
lated datasets. We then provide an interpretation of the
results for each example. We finally discuss the pro-
posed method and its usability.
Method development
Notation, models, and method of testing for
inconsistency
Let θ̂ijk be the observed relative effect size of treatment k
(k= T2, ⋯, Tp) compared to treatment j (j= T0, ⋯, Tp − 1)
from the ith study comparing treatment j versus k where a
network contains p + 1 treatments T0, ⋯, Tp, with θ̂ijk fol-
lowing a normal distribution, Nðθijk ; σ2ijk ). The parameter
θijk is the study-specific treatment effect of treatment k
relative to j in study i. It is conventional that the estimated
variance of θ̂ijk , dvarðθ̂ijkÞ, is treated as if it were the true
variance σ2ijk [26, 27]. The distribution is thus assumed to
satisfy θ̂ijk  Nðθijk ; dvarðθ̂ijkÞÞ . A model of θijk is as
follows:
θijk  Normal djk ; τ2
 
:
Here, djk is the mean study-specific effect size of treat-
ment k compared to treatment j. We used a usual
random-effects model [28, 29], which allows for
between-study variation (τ2) that is common for all com-
parisons in a network. For simplicity, the between-study
variation is assumed to be identical across all contrasts;
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however, between-study variation can also be modeled
separately for each contrast [11, 30].
In the standard approach of performing a network
meta-analysis, the basic parameters dT 0k and dT0 j (j and
k ≠ T0) are first defined using a chosen reference inter-
vention (T0), which is usually placebo or a conventional
treatment [31]. The functional parameter djk (j and k ≠
T0) is then defined by a consistency relationship, djk
¼ dT 0k−dT0 j . A model based on this approach is called a
‘consistency model’. For a simple network with three in-
terventions A, B, and C, the consistency model would
estimate the basic parameters, dAB and dAC, from all
available evidence. The functional parameter, dBC, is cal-
culated using the consistency equation, as dAC − dAB. A
full description of the model is given in Appendix 1
(Additional file 1) for this simple case. In addition, the
network meta-analysis can rank all the treatments from
best to worst [32].
For a star-shaped network where only a common com-
parator (T0) is compared with all other alternative treat-
ments (T1, ⋯, Tp) without any head-to-head comparison
among T1, ⋯, Tp as shown in Fig. 1, T0 is naturally
assigned as the reference treatment in the above model
for performing a network meta-analysis to estimate the
basic parameters, dT 0T1 , ⋯, dT0Tp . The relative effect
sizes among the non-reference treatments are calculated
by indirect comparisons.
An inconsistency model, in which consistency is not
assumed, can be used to check whether the assumption
of consistency holds [13]. This model represents each
contrast between treatments in the network as an unre-
lated basic parameter estimated only from direct evi-
dence; therefore, this is equivalent to conducting a
separate pairwise meta-analysis with a shared heterogen-
eity parameter. For a fully connected simple network,
when direct evidence on all contrasts is available, the in-
consistency model would define the basic parameters,
dAB, dAC, and dBC, without assuming any relationship be-
tween the parameters (see Additional file 1: Appendix
1). In contrast, if direct evidence is not available for one
contrast, say BC, the model would estimate the basic
parameters, dAB and dAC, but the relative effect size be-
tween B versus C cannot be estimated. In a star-shaped
network, there is no difference in fit or estimated treat-
ment effects between consistency and inconsistency
models because the basic parameters are defined identi-
cally in both models.
Consistency and inconsistency models can be fitted in
a Bayesian framework using non-informative prior distri-
butions for each defined parameter. Comparison of re-
sidual deviance and heterogeneity estimates between the
Fig. 1 A graphical representation of a star-shaped network consisting of one common comparator treatment (T0) and p other alternative
treatments (T1, ⋯, Tp). Each node represents an intervention, and a link between two nodes reflects one or more randomized controlled trials
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two models can suggest inconsistency [13, 33]. When
the inconsistency model produces the smallest residual
deviance value, there is potential overall inconsistency in
the corresponding evidence network. Similarly when the
estimated heterogeneity is smaller in the inconsistency
model than in the consistency model, this can suggest
inconsistency. No particular cut-off value was considered
for determining a meaningful difference.
Statistical methods
We considered non-directly connected pairs in a star-
shaped network as missing to conduct a sensitivity
analysis. For a star-shaped network consisting of one
common comparator as a reference treatment, and p
non-reference treatments (Fig. 1), we filled in the hypo-
thetical RCT data for all the p(p − 1)/2 missing pairwise
comparisons, producing fully connected network (here-
after called a ‘complete network’). The imputed data
consisted of study-level treatment effect sizes ( θ̂

ijk ) and
their variances (dvarðθ̂ijkÞ). They were generated to simu-
late a situation that would allow a mixed treatment com-
parison with some extent of inconsistency that is still
acceptable statistically, where the acceptance was deter-
mined by examining whether a consistency model has a
lower residual deviance value than an inconsistency
model, so that the complete network resulting from im-
putation can be aggregated under the consistency as-
sumption. By comparing the agreement between the
analysis results from the original star-shaped network
and the complete network, the robustness of the results
of the original star-shaped network meta-analysis was
assessed.
Imputation strategy
For the p(p − 1)/2 contrasts among non-reference treat-
ments in the star-shaped network, the imputed data
were generated to meet the following conditions:
 I: For each contrast between specific treatments, if
the effect size estimated from the original star-
shaped network is positive (or negative), the pooled
effect size from a pairwise meta-analysis of the im-
puted data is assumed to be less (or greater) than
that indirectly produced from the original star-
shaped network meta-analysis. This condition is put
in place to run the sensitivity analysis from a conser-
vative point of view, assuming that the artificial dir-
ect estimate is smaller (or larger) than the observed
indirect estimate.
 II: For each contrast, the precision of the pooled
effect size from the pairwise meta-analysis of the im-
puted data is the same as the precision of the effect
size indirectly estimated in the original star-shaped
network meta-analysis. This means that the variance
of individually imputed effect sizes will produce
the maximal variance in their pooled effect size,
since it is generally considered that indirectly esti-
mated effect sizes have greater variance than dir-
ect estimates [30].
 III: For each contrast, the extent of heterogeneity in
the imputed data for the effect size of the contrast is
the same as that of the overall heterogeneity across
contrasts in the star-shaped network. This assump-
tion serves to maintain the level of overall hetero-
geneity in the network after imputation, enabling us
to investigate only the impact of the potential extent
of inconsistency on the results of the sensitivity
analysis.
Assessing the robustness of conclusions from a star-shaped
network meta-analysis through imputation
We illustrated the sensitivity analysis method using the
simplest star-shaped network, which involved RCTs of A
versus B and A versus C. The RCT data, θ̂iAB with dvarð
θ̂iABÞ for i = 1, …, N and θ̂iAC with dvarðθ̂iACÞ for i = 1, …,
M, are given, when N and M are the numbers of RCTs for
A versus B and A versus C, respectively. From the star-
shaped network meta-analysis, we obtained estimates of
the basic parameters, d̂AB and d̂AC , and an estimate of
between-study variation, τ̂2 . The indirectly estimated ef-




iBC and dvarðθ̂iBCÞ, with i = 1, …, l for l
hypothetical RCTs comparing B and C using the imput-
ation strategy described in the above section. The value









iBC  N θiBC ; dvar θ̂iBC
  
; for i ¼ 1;…; l:
The imputation parameters, θ1BC , ⋯; θ

lBC , were gener-
ated from a normal distribution, Nðd̂AC−d̂AB þ ωBC ; τ̂2Þ.
The constant ωBC was defined artificially to represent
the extent of potential inconsistency between the direct (
θ̂

BC ) and indirect ( d̂AC−d̂AB ) evidence. Under condition
I, if d̂AC−d̂AB < 0, ωBC should be positive, and if d̂AC−
d̂AB > 0, ωBC should be negative.
The variances dvarðθ̂1BCÞ ¼ dvarðθ̂2BCÞ ¼ ⋯ ¼ dvarð
θ̂

lBCÞ ¼ l∙dvarðd̂AC−d̂ABÞ−τ̂2 were calculated to satisfy
the given conditions (II, III), and they were set up to be
identical for simplicity (the derivation of this formula
can be found in Additional file 1: Appendix 2). However,
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l was an arbitrarily chosen number, with the restriction
that l∙dvarðd̂AC−d̂ABÞ was larger than τ̂2:
To account for potential uncertainty in the prediction
of unknown data for the missing comparisons in a star-
shaped network, we used a multiple imputation ap-
proach. From the defined distribution, the complete net-
work data with imputations were generated m times and
each of the m complete networks was analyzed using the
consistency model. The resulting estimate of each par-
ameter with its variance and the estimated probability of
each treatment being the best were obtained by Rubin’s
rules [34, 35], and each treatment was then ranked using
the obtained probabilities. When pooling by Rubin’s
rules [34, 35], the estimate of each parameter is summa-
rized by taking the average over estimates from all im-
puted m complete networks, and its variance is
produced by incorporating both within-imputation and
between-imputation variability.
The above processes were repeated, changing the value
of j ωBC j to increase from zero until the complete net-
work started to have a larger residual deviance value
when the consistency model was applied than when the
inconsistency model was applied, which produced a
range of values for jωBC j that can be considered statisti-
cally acceptable for a synthesis by network meta-analysis
under the consistency assumption. The value of m was
determined as the point where the two residual deviance
curves crossed only once and never again, that is where
the threshold value was stabilized. The proportion of j
ωBC j values that resulted in a consistent ranking of
treatments to that from the original star-shaped network
meta-analysis was presented as a percentage, as an indi-
cator of the sensitivity of the results to the degree of po-
tential inconsistency. A “consistent ranking” meant that
the order of the originally observed ranking was
unchanged.
The sensitivity analysis may be generalized to a star-
shaped network with more than three interventions by
employing ωjk for j = T1, ⋯, Tp − 1 and k = T2, ⋯, Tp (j ≠
k). We demonstrated this case with p = 3, where ωjk for j
¼ T 1;T 2 and k = T2, T3 (j ≠ k) were simultaneously
changed by an identical magnitude from zero in their re-
spective directions.
The developed method was implemented in R software
(version 3.3.3) [36].
Application to datasets
Illustration of the method: smoking cessation dataset
To illustrate how the method can be applied, a dataset
was drawn from a published and well-studied network
meta-analysis [11, 16, 37] comparing four smoking ces-
sation treatments: no intervention (NI), self-help (SH),
individual counseling (IC) and group counseling (GC).
The relative effect was measured by the logarithm of the
odds ratio for successful smoking cessation at 6–12
months. There were 24 RCTs including two three-arm
trials. In the original analyses, both the global model fit
statistics and the inconsistency p-value suggested no
presence of inconsistency (Additional file 2: Table S1).
The reported overall measure of inconsistency, taken as
the variance of inconsistency factor, was 0.61; this value
was smaller than the value of between-study heterogen-
eity (0.78), suggesting an acceptable extent of inconsist-
ency. The posterior distributions of the direct estimates
overlapped with those of the estimates obtained using
indirect evidence for all contrasts [16].
In this exercise, we utilized only the 22 two-arm trials
(Fig. 2a). A network meta-analysis was conducted using
the consistency model to produce estimates of the basic
parameters, dNI, SH, dNI, IC, and dNI, GC, where NI was
the reference treatment. A ranking of the treatments
was determined using the estimated probability for each
treatment to be the best from this model.
We formed a star-shaped network by discarding data
from the four RCTs that compared non-reference
treatments head-to-head (Fig. 2b). For the intended star-
shaped network, we initially performed a network meta-
analysis using the consistency model. We subsequently
applied the proposed method for sensitivity analysis.
From the sensitivity analysis, according to the absolute
extent of inconsistency, jωjk j (j= SH, IC, and k = IC, GC,
j ≠ k), we plotted traces of residual deviances from the
consistency and inconsistency models against the corre-
sponding jωjk j and indicated the point where those two
curves crossed. Estimates of the basic parameters with
their 95% credible intervals (CrIs), the probability that
each treatment was the best for smoking cessation, and
the treatment ranking were also plotted for each value of
jωjk j up to this point. The proportion of jωjk j that re-
sulted in a consistent ranking of treatments to that ob-
tained from the star-shaped network meta-analysis was
presented. To determine the number of imputations, we
started with an imputation number of 100 and increased
it by 100 until a stabilization of threshold was obtained
at 500 imputations (Additional file 3: Figure S1).
Simulation for diverse scenarios
Datasets from a simple star-shaped network of RCTs of
A versus B and A versus C were simulated according to
levels of within- and between-study variability of treat-
ment effect size (i.e., the standard errors of estimates
from the individual trials and the extent of overall
heterogeneity across contrasts) (see Additional file 2:
Table S2). For each dataset, the number of trials for each
contrast was set to be five. The effect sizes for each con-
trast were arbitrarily chosen to be a specified value when
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they were pooled, and to have a specific level of het-
erogeneity that was determined in terms of the I2
statistic. This statistic was used under the assumption
that the effect sizes were normally distributed sample
means. To consider differences in the treatment effect
among the three interventions, the pooled treatment
effect sizes for the comparisons (A versus B and A
versus C) were set at 0.5 and 1 for the effect size of
one alternative treatment relative to the reference
treatment to be half of that of another alternative
treatment relative to the reference treatment. We
then generated individual trial-level effect sizes with
their standard errors to comply with the condition
that the probability for each treatment group being
the best would be 0.66 for C, 0.33 for B, and 0 for A, re-
spectively, while no heterogeneity existed. Starting from
this basic scenario, we modified the level of standard error





sponds to the impact of doubling the variance while
attempting to increase the scale of heterogeneity to the se-
vere level. The considered values of the I2 statistic were
0% (no heterogeneity), 40% (moderate heterogeneity), and
70% (severe heterogeneity) [38].
This method was applied to each dataset. According
to the absolute extent of inconsistency, represented by j
ωBC j , we plotted traces of residual deviances from the
consistency and inconsistency models, and then indi-
cated the point where those curves crossed. The prob-
ability of each treatment group being the most effective
was plotted for each value of jωBC j up to this point. The
proportion of jωBC j values that resulted in a ranking of
treatments consistent with the original ranking in the
star-shaped network was presented. For each simulated
dataset, we ran the process by applying a sufficiently
large number of imputations (500).
Extension of application: Crohn’s disease dataset
We demonstrated the extended usability of our method
by considering network meta-analyses that are conducted
in contexts where few closed loops are available. From an
original network in a recently published review conducted
to compare the effects of interventions for the mainten-
ance of surgically induced remission in Crohn’s disease
[39], a sub-network consisting of placebo, purine ana-
logues, 5-aminosalicylic acid (5-ASA), adalimumab, and
infliximab was abstracted (see Additional file 3: Figure S2
(a)). The relative effect was measured by the logarithm of
the risk ratio for clinical relapse.
We plotted traces of residual deviances from the
consistency and inconsistency models according to jωjk j
(j = placebo, k = adalimumab, infliximab, and j = 5 −
ASA, k = infliximab), with an indication of the point
where those two curves crossed. Since purine analogues
were most frequently connected with other alternative
treatments in the network, we chose them as the refer-
ence treatment. The estimates of the basic parameters
and the probability to be the best treatment for redu-
cing relapse were also plotted for each value of jωjk j
up to this point. The proportion of jωjk j values that
resulted in a consistent ranking of treatments com-
pared to that obtained from the star-shaped network
meta-analysis was presented. Since the example data-
set contained two three arm trials, we used the
shared parameter model [31] to incorporate both the
arm-level and the trial-level data into the analysis.
We set the number of imputations to 500.
Results of application
Smoking cessation dataset
When the consistency model was applied to the





Fig. 2 a A graphical representation of the evidence network for four smoking cessation counseling programs. b A graphical representation of the
derived star-shaped network by eliminating four trials corresponding to direct comparisons among self-help, individual counseling, and group
counseling. Each node represents an intervention, and a line between two nodes reflects one or more randomized controlled trials (RCTs). The
numbers on each solid line connecting two interventions correspond to the number of RCTs comparing those interventions
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and d̂
c
NI ;GC were 0.43 (95% CrI, − 0.38 to 1.25), 0.73 (0.26
to 1.20), and 1.38 (0.25 to 2.5), respectively, and the best
treatment for smoking cessation was GC, followed by IC,
SH, and NI (Additional file 2: Table S3). The star-shaped
network formed by discarding the head-to-head contrast
data produced d̂
s
NI ;SH , d̂
s
NI;IC , and d̂
s
NI;GC values of 0.33
(− 0.73 to 1.39), 0.72 (0.19 to 1.25), and 3.52 (0.12 to
6.93), respectively, with the same order of ranking. How-
ever, the estimate, d̂
s
NI ;GC , which was obtained only from
direct evidence, was more exaggerated than d̂
c
NI;GC , and
the probability of GC being the best intervention for
smoking cessation became even higher.
The range of jωjk j for statistically acceptable inconsist-
ency was approximately from zero to 1.05 (Fig. 3), the
upper threshold of which is a value in the middle of the





NI;IC , and d̂
s
NI;GC . As jωjk j increased, the esti-
mate of dNI, SH increased and the estimate of dNI, GC de-
creased (Fig. 4). The estimates of basic parameters
became closer to each other, and the exaggerated prob-
ability of GC being the best intervention decreased to a
level similar to the findings obtained from the original
complete network (Fig. 5a), and the order of the ranking
then changed (Fig. 5b). The proportion of jωjk j values
that produced a treatment ranking consistent with that
from the star-shaped network meta-analysis was ap-
proximately 67%.
Simulated datasets
For a given effect size, a star-shaped network with a
greater level of between-study (or within-study) variabil-
ity, when the level of within-study (or between-study)
variability was fixed, produced a larger threshold of jωAB
j at which the residual deviance curves from the two
models intersected (Additional file 3: Figure S3). The
threshold showed that a greater extent of uncertainty
present in an evidence network allowed a higher level of
actual inconsistency to be acceptable. Within the range
extending up to the threshold, the proportion of jωABj
values that produced a consistent ranking of the treat-
ments with the original ranking was smaller (Fig. 6). A
small proportion indicates that the conclusions from the
complete networks, simulated under assumption that
there was no inconsistency, could have a great possibility
of differing from the conclusions of the original star-
shaped network.
In the network with the basic scenario, the proportion
of jωBC j values that produced a treatment ranking con-
sistent with that from the star-shaped network meta-
analysis was approximately 69% (Fig. 6d). In the absence
of heterogeneity, when only the standard error was
modified by halving it or to double the variance, the
proportion increased to 100% and decreased to 48%, re-
spectively (Fig. 6a and g). While keeping the level of
standard error, as I2 increased to 40% and then to 70%,
the proportion decreased to 65 and 42%, respectively
(Fig. 6e and f).
Crohn’s disease dataset
The range of jωjk j for statistically acceptable inconsist-
ency was zero to approximately 1.7 (see Additional file 3:
Figure S2 (b)), where the obtained maximum value was
located roughly in the middle of the half widths of the
originally estimated 95% CrIs of the four basic parame-
ters. As jωjk j increased, the estimates of basic parame-
ters became closer to each other, but none were
reversed in ranking (Additional file 3: Figure S2 (c)). The
proportion of jωjk j values that produced a treatment
ranking consistent with that from the original network
meta-analysis was then 100% (Additional file 3: Figure
S2 (d)). This can therefore strengthen confidence in the
results from the original network meta-analysis.
Discussion
In practice, we occasionally come across a situation
where health technologies of interest have never been
compared against each other, but it is still necessary to
assess their comparative effectiveness based only on a
star-shaped network meta-analysis under the unverifi-
able consistency assumption. We have developed a
method for sensitivity analysis that accounts for an un-
known degree of inconsistency by imputing data for all
missing pairwise comparisons in a star-shaped network.
We established the imputation strategy based on the
following rationale. If the effect size for each contrast es-
timated from the original star-shaped network is positive
(or negative), the pooled effect size from a pairwise
meta-analysis of the imputed data is less (or greater)
than that. We set up this condition to run the sensitivity
analysis from a conservative perspective, as the observed
treatment difference (from indirect information only)
should be considered biased if the true difference is
closer to the null or if the direction of the effect may be
different. In reality, the true difference might be one that
even strengthens the existing conclusion, but we did not
deal with such cases, since they would then not be a
cause for concern and therefore beyond our scope. We
also assumed that the precision of the pooled effect size
obtained from the pairwise meta-analysis of the imputed
data would be equal to the precision of the effect size
obtained indirectly from the original star-shaped net-
work meta-analysis. This equality implies that the vari-
ance of individually imputed effect sizes will produce the
maximal variance of their pooled effect size. This could
be considered as the most conservative case. If some
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information is available on the precision of the unknown
direct estimate, regarding how relatively small it could
be, it is possible to take that information into account in
the equation of dvarðθ̂iBCÞ to the variance of indirectly
obtained estimate as a proportion.
We established the extent of heterogeneity in the im-
puted effect sizes necessary for each missing contrast to
have the same level as the overall heterogeneity in the
original star-shaped network. Unless the numbers of
studies within contrasts are sufficiently large, it may be
hard to estimate the overall heterogeneity, and any exist-
ing heterogeneity could be dramatically exaggerated. To
take such cases into account, our simulation study con-
sidered a condition with severe heterogeneity. Further-
more, in practice, the number of included studies in a
network meta-analysis is often insufficient to precisely
estimate the heterogeneity variance. In that case, we may
consider informative priors for heterogeneity variance to
incorporate some external evidence into the network
meta-analysis model [40, 41] in our method as an at-
tempt to overcome this problem.
In this method, for a star-shaped network consisting
of one common comparator and p alternative treat-
ments, we imputed data for p(p − 1)/2 missing contrasts.
If p is 2, 3, 4, or 5, the number of contrasts for data im-
putation would be 1, 3, 6, or 10, respectively. When p ≥
4, the number of missing contrasts becomes larger than
the number of connected contrasts, meaning that the
proportion of unknown information is high. Therefore,
for a star-shaped network where p ≥ 4, it may not be
Fig. 3 Residual deviances by model type (y-axis) against the absolute extent of inconsistency (x-axis). The solid line and dashed line indicate the
consistency model and inconsistency model, respectively. A vertical line marks the point at which the two lines cross, and the value of that point
on the x-axis is shown
Yoon et al. BMC Medical Research Methodology          (2021) 21:113 Page 8 of 15
recommended to apply this method because data imput-
ation may inordinately neutralize the evidence contained
in the star-shaped network. When the proportion of
missing contrasts is relatively small in a network involv-
ing more than 4 alternative treatments, but including
few head-to-head comparisons, our suggested method
can be used, and we presented the extended usability of
this method through the example using a Crohn’s dis-
ease dataset.
Since the unit of imputed data in a network meta-
analysis is a trial, the proportion of missing information
is usually higher than that in ordinary applications.
Therefore, a large number of imputations are required
to stabilize the results of the sensitivity analysis through
a multiple imputation strategy [34, 35]. In another ex-
ample of meta-regression, the number of imputations
was increased to 100 [42]. In our approach, stabilization
was defined as occurring once the residual deviance
curves of two models crossed and never overlapped
again. The number of imputed complete networks, m,
should be determined during the analysis depending on
the data. For the smoking cessation example, the ex-
ploratory results by different numbers of imputations
(m = 100, 200, 300, 400 and 500) in Additional file 3:
Figure S1 suggest that 500 was sufficient. We also ex-
plored the number with several simulated datasets to
confirm that repeating imputations 500 times is suffi-
cient to achieve stabilization. Some exploratory residual
deviance plots demonstrate that a much smaller number,
such as 100, may be enough (Additional file 3: Figure
S4). However, we recommend just applying a large num-
ber, such as 500, rather than running the exploration
process for choosing the number of imputations per
dataset, which would save much greater computational
intensity.
The imputed data consisted of study-level treatment
effect sizes ( θ̂

ijk ) and their variances ( dvarðθ̂ijkÞ ). We
established the assumption that the variances of the ef-
fect sizes for each contrast would be identical. According
to the conditions described in the “Imputation strategy”
section, the variances were calculated so that, for each
contrast, the variance of the pooled effect size of the im-
puted data would be the same as that of the indirectly
estimated effect size from the original star-shaped net-
work meta-analysis. Since it is the precision of pooled
estimate of the imputed effect sizes that contributes to
estimation of basic parameters in the resulting network
meta-analysis after imputation, any combination of
Fig. 4 Interval plot of estimates of basic parameters against the extent of inconsistency (x-axis) within the obtained range. The black square, gray
circle, and dim gray triangle symbols indicate the estimated treatment effect sizes for self-help, individual counseling, and group counseling
compared to no intervention, with the vertical lines extending from the symbols representing 95% credible intervals
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values for the individual variances is acceptable as long
as the overall precision is satisfying the condition. In the
same context, for each contrast, we allowed the number
of trials (l) to be arbitrarily chosen under the restriction
that l∙dvarðd̂Ak−d̂AjÞ (j ≠ k ≠A) is larger than τ̂2: A trade-
off exists between l and 1=dvarðθ̂ijkÞ.
Methods of testing the consistency assumption are dis-
tinguished by how to treat inconsistency. The Bucher
method [15], the back-calculation method, and the
node-splitting method [16] are local test methods that
evaluate the inconsistency of each contrast that consti-
tutes a network. Global test methods assess the compre-
hensive inconsistency of the network based on
modeling. The types of models used for testing include a
random-inconsistency Bayesian model [11], a design-by-
treatment interaction model [17], and an inconsistency
model with unrelated mean relative effects [13]. For our
Fig. 5 a Probability that each treatment is the best for smoking cessation against the extent of inconsistency within the obtained range. b
Ranking of each treatment for successful smoking cessation against the extent of inconsistency within the obtained range. The gray dotted, gray
solid, black solid, and black dotted lines indicate the probabilities and rankings corresponding to no intervention, self-help, individual counseling,
and group counseling, respectively. A vertical line marks the point at which some lines cross, and the percentages in the dark gray and dim gray
boxes represent the proportions of jωjk j that resulted in a consistent ranking and an inconsistent ranking of treatments relative to the original
ranking, respectively
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method, we tried to assess the overall inconsistency in
the network according to the magnitude of potential
inconsistency, for which a global testing approach was
appropriate. Our sensitivity analysis was based on the
idea of data imputation for missing contrasts in a star-
shaped network, which requires limiting the number of
loops to be closed. We therefore adopted an inconsist-
ency model with unrelated mean relative effects, rather
than a model estimating inconsistency factors, which is
not recommended unless the number of closed loops is
sufficiently large [13].
In the smoking cessation example, we showed that the
sensitivity analysis may successfully simulate some
expected results from an unknown complete network. In
the full network, including all 24 RCTs, the estimated
absolute extent of inconsistency for the contrasts ranged
from 0.17 to 1.7 [16]. In our sensitivity analysis, the
maximum obtained value assumed to be common for all
contrasts was 1.05, a value in the middle of the above
range. Regarding the robustness of the results of the
star-shaped network, we could conclude that in 33% of
the sensitivity analyses undertaken with statistically ac-
ceptable inconsistency, the resulting treatment ranking
would be inconsistent with the ranking from the star-
shaped network. These results suggest that a star-shaped






69% 31% 65% 35% 42% 58%
48% 52%
43% 57% 37% 63%
Fig. 6 Probability of each group being the best (y-axis) against the extent of inconsistency, jωBC j (x-axis), within the obtained range for each data
set. a when I2 is 0% and the standard error is 1, b when I2 is 40% and the standard error is 1, c when I2 is 70% and the standard error is 1, d
when I2 is 0% and the standard error is 2, and e when I2 is 40% and the standard error is 2, f when I2 is 70% and the standard error is 2, g when













black dotted, gray solid, and black solid lines indicate the probability corresponding to groups a, b, and c, respectively. A vertical line marks the
point at which some lines cross, and the percentages in the dark gray and dim gray boxes represent the proportions of jωBC j that resulted in a
consistent ranking and an inconsistent ranking of treatments relative to the original ranking, respectively
Yoon et al. BMC Medical Research Methodology          (2021) 21:113 Page 11 of 15
caution unless the obtained treatment ranking is shown
to be robust to uncertainty of the unverifiable
consistency assumption.
In the application to simulated datasets, we demon-
strated the sensitivity of the results after data imputation
against the synthesis results from a given star-shaped
network with different levels of within- and between-
study variability. In a network meta-analysis, both incon-
sistency and heterogeneity can be caused by some com-
mon sources, such as differences in some effect
modifiers, which are closely related to each other [13].
For this reason, performing a star-shaped network meta-
analysis using a consistency model may be considered
more valid when a lower level of heterogeneity within
the network is present.
When we considered a star-shaped network with more
than three interventions, we assumed that ωjk for j = T2,
⋯, Tp − 1 and k = T3, ⋯, Tp (j ≠ k) would be simultan-
eously changed by an identical magnitude from 0 in
their respective directions. However, it is also possible to
assign different levels of inconsistency if there is an ap-
propriate rationale for doing so. For example, in the full
known complete network of the smoking cessation
meta-analysis, there was a contrast for which the incon-
sistency estimate was observed to be somewhat larger
than others, although no statistically significant incon-
sistency was found overall. If prior information was
available on the diversity of the extent of inconsistency
for the contrasts, taking such considerations into ac-
count may point to ways to further refine how to under-
take a sensitivity analysis.
Some limitations of this study motivate further research.
First, the estimated variance of each individual trial was
treated as if it were the true variance in the network meta-
analysis models in our approach. However, the variances
themselves are given in the form of estimates, and it there-
fore might be necessary to consider uncertainty in the
variances [43, 44]. A further investigation to introduce a
probability distribution for the estimated variances would
be worthwhile. Second, we used a point estimate of
heterogeneity from a star-shaped network meta-analysis
for the data imputation process. However, further research
may consider generating the estimate of heterogeneity
from its posterior distribution. Third, we built up a
method that can be applied to a general form of compara-
tive measure that follows at least asymptotic normality.
This assumes using a log transformation for a ratio type of
measure, such as log odds ratios or log relative risks, when
a binary outcome was considered. However, since there is
a correlation between log odds ratios (or log risk ratios)
and their estimated variances, there could be an issue on
pooling the estimates by the inverse variance weight
method. An arm-specific data imputation strategy with
arm-based modeling that accounts for specific types of
outcome measures could also be considered for an elabor-
ation of our method.
We defined consistency in the ranking as an un-
changed order of the originally observed ranking. How-
ever, a change of ranking may not necessarily be
interpreted as indicating an inconsistency in the results,
depending on the probability difference based on which
the order was obtained. Although the observed ranks
were switched between treatments, their associated
probabilities of being the best treatment might not be
considered significantly different, as we observed from
the overlapping distributions of probabilities in Add-
itional file 3: Figure S5 for the smoking cessation ex-
ample. However, it is a convention that authors report
treatment rankings based only on the order of probabil-
ities, and we tried to demonstrate how likely it was for
the originally obtained conclusion from a star-shaped
network to remain robust in terms of the order of rank-
ings that authors would report.
An approach known as ‘threshold analysis’, based on a
similar conceptual framework of sensitivity analysis to
assess confidence in recommendations obtained from
network meta-analyses, has been proposed in the litera-
ture [45–47]. Threshold analysis derives a set of thresh-
olds that describe how much each data point from a
study or contrast could change before the recommenda-
tion changes. This method could also be applied to a
star-shaped network, such as the example created from
the smoking cessation meta-analysis. Figure S6 in Add-
itional file 3 presents results from the threshold analysis
for the star-shaped network at the contrast level. If the
invariant interval is within the 95% credible interval of
the effect size for each contrast from a base-case star-
shaped network meta-analysis in this context, it is inter-
preted that the optimal treatment recommendation
could change. The result suggests some possibility of IC
being optimal, instead of GC. Since only one study was
available in the analysis in which GC was compared to
NI, a wide credible interval for their relative effects was
produced. As a result, the sensitivity analysis suggests
that some potential change in the effect size estimate
from its currently observed value—even within the range
of the credible interval—could have changed the current
recommendation to the second best option, IC.
In contrast with the results from the threshold analysis
method, our approach suggested that the ranking of GC
as distinctly more effective than other treatments would
remain stable, whereas the rankings of IC and NI may
be switched. Although both approaches utilize sensitivity
analysis, they were designed to incorporate different
concerns: the impact of potential bias in the given direct
data or the impact of potential inconsistency between
observed indirect evidence and non-existing direct data.
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The discrepancy in the results may stem from the fact
that these approaches focus on different features.
Where individual patient data (IPD) are available for
at least one of the trials included in a star-shaped net-
work meta-analysis, methods for population-adjusted in-
direct comparisons, such as the matching-adjusted
indirect comparison and the simulated indirect compari-
son, could be applied with improving balance in patient
characteristics between the trials [48–50]. These
population adjustment methods apply both to anchored
comparisons and unanchored comparisons without a
common comparator [51]. If there is a lack of overlap
between IPD and aggregate data populations, it is neces-
sary to assess the robustness of the comparisons because
these methods may produce biased estimates, and our
proposed method of sensitivity analysis will be a useful
tool. Furthermore, when no IPD are accessible and if it
is determined that the studies are highly exchangeable,
researchers may just attempt to integrate data through a
network meta-analysis using a consistency model. Our
proposed method could serve as an alternative approach
to assess the reliability of results from a star-shaped
network before making a conclusion relying on those
results.
Conclusions
Our method will serve as a practical technique to inves-
tigate the reliability of results from star-shaped network
meta-analyses under the unverifiable consistency as-
sumption, and therefore will help to assess evidence for
use in unbiased clinical decision-making.
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